Pulmonary Fibrosis vs. Pulmonary Sclerosis: Differences in Cause, Progression, and Prognosis
Both cause lung scarring and dyspnea, but differ fundamentally:
| Feature | Pulmonary Fibrosis | Pulmonary Sclerosis |
|---|---|---|
| Etiology | Diverse: toxins (asbestos, silica), drugs, autoimmune, genetic, idiopathic (IPF) | Usually secondary to chronic inflammation (emphysema, chronic bronchitis) |
| Progression | Often rapid, relentless | Slower, more indolent |
| Severity | More severe symptoms, faster decline | Milder, slower functional loss |
| Prognosis | Poorer; median survival 3–5 years (IPF) | Better long-term outlook |
| Treatment | Antifibrotics (nintedanib, pirfenidone), O₂, rehab, transplant | Treat underlying cause, O₂, rehab; transplant rarely needed |
Accurate diagnosis (HRCT, biopsy, PFTs) guides therapy. Both benefit from pulmonary rehabilitation and oxygen if hypoxemic.
Multiple Sclerosis - Related Articles
- Understanding Early Multiple Sclerosis Symptoms: What to Watch For
- Primary Progressive MS: Symptoms, Causes & What to Expect
- Multiple Sclerosis and Oligodendrocytes: The Target of Autoimmune Attack
- Leg Weakness in Multiple Sclerosis (MS): Causes & Symptoms
- Ultimate Travel Checklist for People with MS
- Comprehensive Guide to Multiple Sclerosis (MS) Treatments
- Multiple Sclerosis: A Step-by-Step Guide to Diagnosis, Treatment, and Support
